Short answer
Neuronetics, Inc. (STIM) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $34M (up 7.8% year over year) with net income of −$11M.
Q1 2026 key financials · XBRL
- Revenue
- $34M
- +7.8% YoY
- Net income
- −$11M
- +14.9% YoY
- Operating margin
- -26.1%
- Gross margin
- 46.9%
- EPS (diluted)
- −$0.16
- +23.8% YoY
Source: XBRL data from the Neuronetics, Inc. (STIM) Q1 2026 10-Q on SEC EDGAR. USD.
Neuronetics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $34.5M, up $2.5M or 8% YoY from $32.0M
- Clinic revenue largest category, 63% of U.S. revenue; treatment sessions 27% and Systems 9%
- Net loss $10.8M vs $12.7M YoY; no margin percentages disclosed
- U.S. revenue $34.2M, up 9% YoY from $31.5M, primarily clinic revenue growth
- Management expects clinic revenue to increase in 2026; macroeconomic pressures remain headwinds
Risk Factors
- Newly added geopolitical risk: Middle East tensions involving Iran driving market volatility, inflation, supply-chain disruption, and higher raw-material costs
- Most material financial update: Substantial doubt about going concern due to projected trailing-twelve-month revenue below Perceptive Facility minimum for March 31, 2027
- Regulatory risk: FCA Civil Investigative Demand and parallel state investigations into pre-acquisition Greenbrook TMS federal healthcare billing practices
- Operational risk: Potential supply-chain disruptions and transaction restrictions affecting product availability and business costs
- Liquidity risk: Recurring losses and negative cash flow may require additional financing on unfavorable terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neuronetics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.